CN Patent

CN111182893A — 包含f6h8的眼用组合物

Assigned to Novaliq GmbH · Expires 2020-05-19 · 6y expired

What this patent protects

本公开提供使用包含半氟化烷烃的眼用组合物治疗干燥性角膜结膜炎和/或睑板腺功能障碍的方法，该方法提供眼部组织富集半氟化烷烃，以及任选地半氟化烷烃从富集的眼部组织至角膜和/或结膜的表面和/或至睑板腺的延迟释放的方法。

USPTO Abstract

本公开提供使用包含半氟化烷烃的眼用组合物治疗干燥性角膜结膜炎和/或睑板腺功能障碍的方法，该方法提供眼部组织富集半氟化烷烃，以及任选地半氟化烷烃从富集的眼部组织至角膜和/或结膜的表面和/或至睑板腺的延迟释放的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN111182893A
Jurisdiction
CN
Classification
—
Expires
2020-05-19
Drug substance claim
No
Drug product claim
No
Assignee
Novaliq GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.